Sinovac Biotech gets Chinese license to make flu vaccine

Sinovac Biotech said that China's State Food and Drug Administration (SFDA) issued a production license for Sinovac's proprietary influenza flu vaccine, Anflu. Though the company already had won a new drug certificate from the Chinese government for the vaccine, it required a separate license to start production. The company has established its flu production line, which has a capacity of 2 million doses per year. Sales are expected to begin in the last quarter of 2005.

- read this press release for more

PLUS: SinoFresh achieves in vitro success with antiviral nasal spray. Release

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.